Johnson Chemical Pharmaceutical reported its 2025 net profit of NT$53.5 million, with an EPS of $1.19. The board approved a cash dividend of NT$1.05 per share, representing a high payout ratio of 88%.

• Strategic Investment: Johnson Chemical has increased its stake in Genovate Biotechnology to 17.71%. In a significant move, the board authorized an additional investment of up to NT$250 million to purchase further shares of Genovate Biotechnology on the open market. This announcement serves as a formal signal of the company's intent to proceed with a merger or acquisition.
• Operational Stability: Despite a slight dip in February revenue due to the Lunar New Year holidays, Johnson maintained stable gross and operating margins at 40% and 13%, respectively, while focusing on optimizing inventory and adjusting its product mix for 2026.

Resource: 強生去年EPS 1.19元，擬再加碼最多2.5億元買健亞股票